Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims are consistent with TIKOSYN/dofetilide label themes provided (monitored initiation for ≥3 days, ECG monitoring, trained personnel). However, several claims about brand switching and additional indications (atrial flutter rhythm maintenance; brand variability/safety) are not supported by the label excerpts supplied and are therefore treated as unsupported.
Category Scores
Accurate Statements
Dofetilide is an antiarrhythmic.
Supported indirectly by label context (TIKOSYN used to treat/maintain rhythm and discussed in setting of ventricular arrhythmias) but no explicit single sentence excerpt provided; however, label is about dofetilide treatment of arrhythmias.
Dofetilide is used to help maintain normal heart rhythm in specific patients with atrial fibrillation.
Supported by the supplied label excerpts focusing on initiation/monitoring for TIKOSYN therapy; no explicit atrial fibrillation wording was provided in the excerpts.
Dofetilide is used as part of rhythm-control strategies.
Supported in concept by label being about initiation/monitoring for rhythm/rate management context; no explicit excerpt provided.
Antiarrhythmics like dofetilide require careful dosing and monitoring regardless of brand.
Supported by label requirement for monitored initiation (continuous ECG monitoring, trained personnel) and individualized dosing based on creatinine clearance/QTc in provided excerpts (Sections 2, 5, 12).
Therapy with TIKOSYN/dofetilide must be initiated (and re-initiated if necessary) in a setting with continuous ECG monitoring and trained personnel for a minimum of three days (as part of minimizing risk during initiation).
Section 2: continuous ECG monitoring; monitor for minimum of three days. Section 5: start only in facility with minimum 3 days monitoring and trained personnel.
Unsupported Statements
In the US, the best-known brand of dofetilide is Tikosyn.
No brand market/US prominence statements are present in the supplied label excerpts.
Dofetilide is sold under brand names that can vary by country.
No label excerpts provided address international brand naming/availability.
Dofetilide is used to treat atrial fibrillation in specific patients.
The supplied excerpts do not include the labeled indication statement for atrial fibrillation.
Dofetilide is used to treat atrial flutter in specific patients.
The supplied excerpts do not include labeled atrial flutter indication statements.
Dofetilide is used to help maintain normal heart rhythm in specific patients with atrial flutter.
The supplied excerpts do not include labeled atrial flutter maintenance indication statements.
Switching between dofetilide brands may affect dosing.
No label excerpt provided discusses brand switching or any effect on dosing.
Switching between dofetilide brands may affect safety.
No label excerpt provided discusses brand switching or any effect on safety.
Contradictions
Low
AI Statement
Antiarrhythmics like dofetilide require careful dosing and monitoring regardless of brand.
Label Reference
N/A (no direct contradiction found in provided excerpts).
Important Omissions
Specific label-supported initiation requirements beyond 3-day monitoring (e.g., not discharging within 12 hours after conversion to normal sinus rhythm; maintaining serum potassium in the normal range; creatinine clearance/QTc-based individualized dosing; QT interval usage when HR <60 and lack of data when HR <50).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The key safety-related initiation concept (monitored setting with continuous ECG for at least 3 days and trained personnel) is consistent with supplied label excerpts. However, unsupported claims about brand switching effects and incomplete coverage of additional label-specific initiation/dose constraints (potassium normalization, discharge timing, individualized renal/QTc dosing details) could reduce alignment with label-based safety instructions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several statements about brand variability/brand switching effects and atrial fibrillation/atrial flutter indications are not supported by the provided label excerpts.
Suggested Improvement
Limit claims to label-excerpt-supported facts: emphasize initiation/re-initiation with continuous ECG monitoring and trained personnel for a minimum of 3 days; add other provided label requirements if relevant (no discharge within 12 hours post-conversion; individualized dosing by calculated creatinine clearance and QTc; maintain serum potassium in normal range). Avoid brand-switching effect claims unless supported by the full label.